Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing

Canadian Journal of Clinical Pharmacology

Volumn 6, Issue 2, 1999, Pages 103-110

  Busto, Usoa E ^a,b   Zawertailo, Laurie A ^c   Kaplan, Howard L ^b,c   Sellers, Edward M ^b,c,d  

^a Faculty of Pharmacy   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Abuse liability; Hydromorphone; Secobarbital; Subjective effects

Indexed keywords

BARBITURIC ACID DERIVATIVE; HYDROMORPHONE; OPIATE; SECOBARBITAL;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG ABUSE; DRUG DEPENDENCE; DRUG SCREENING; HUMAN; MALE; PSYCHOMOTOR DISORDER;

EID: 0032815522     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Lasagna L, von Feisinger JM, Beecher HK. Drug-induced mood changes in man. 1. Observations on healthy subjects, chronically ill patients and "post-addicts". JAMA 1955;157:1006-20.
2. Schuster CR. Testing for abuse liability of drugs in humans. In: Fischman MW, Mello NK, eds. NIDA Research Monograph No 92. Rockville: United States Department of Health and Human Services, 1989:1-6.
3. Bigelow GE. Human drug abuse liability assessment: Opioids and analgesics. Br J Addict 1991;86:1615-28.
4. Vocci FJ. The necessity and utility of abuse liability evaluation in human subjects. Br J Addict 1991;86:1537-42.
5. Jasinski DR. History of abuse liability testing in humans. Br J Addict 1991;86:1559-62.
6. Foltin RW, Fischman MW. Assessment of the abuse liability of stimulant drugs in humans: A methodological survey. Drug Alcohol Depend 1991;28:3-48.
7. Evans SM, Critchfield TS, Griffiths RR. Abuse liability assessment of anxiolytics/hypnotics: Rational and laboratory lore. Br J Addict 1991;86:1625-32.
8. Busto U, Kaplan HL, Zawertailo L, Sellers EM. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin Pharmacol Ther 1994;55:451-63.
9. Zawertailo L, Busto U, Kaplan HL, Sellers EM. Comparative abuse liability of sertraline, alprazolam, and dextro-amphetamine in humans. J Clin Psychopharmacol 1995;15:117-24.
10. Henningfield JE, Migasoto K, Jasinski DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 1985;234:1-20.
11. Stern KN, Chait LD, Johanson CE. Reinforcing and subjective effects of caffeine in humans. Psychopharmacology 1989;98:81-8.
12. Pickens R, Cunningham MR, Heston LL, Eckert E, Gustafson LK. Dose preference during pentobarbital self-administration by humans. J Pharmacol Exp Ther 1977;203:310-8.
13. Griffiths RR, Bigelow GE, Liebson I. Human sedative self-administration: Double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. J Pharmacol Exp Ther 1979;210:301-10.
14. Griffiths RR, Bigelow GE, Liebson I, Kaliszak JE. Drug preference in humans: Double-blind choice comparison of pentobarbital, diazepam, and placebo. J Pharmacol Exp Ther 1980;215:649-61.
15. Roache JD, Griffiths RR. Comparison of triazolam and pentobarbital: Performance impairment, subjective effects, and abuse liability. J Pharmacol Exp Ther 1985;234:120-33.
16. de Wit H, Griffiths RR. Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend 1991;28:83-111.
17. de Wit H, Uhlenhuth EH, Johanson CE. Lack of preference for flurazepam in normal volunteers. Pharmacol Biochem Behav 1984;21:865-9.
18. de Wit H, Uhlenhuth EH, Hedeker D, McCracken SJ, Johanson CE. Lack of preference for diazepam in anxious volunteers. Arch Gen Psychiatry 1986;43:533-41.
19. de Wit H, Pierri J, Johanson CE. Reinforcing and subjective effects of diazepam in non-drug abusing volunteers. Pharmacol Biochem Behav 1989;33:205-13.
20. Sellers EM, Schneiderman JF, Romach MK, Kaplan HL, Somer GR. Comparative drug effects and abuse liability of lorazepam, buspirone and secobarbital in nondependent individuals. J Clin Psychopharmacol 1992;12:79-85.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, Revised. Washington: American Psychiatric Association, 1987.
22. Derogatis LR. Symptom Check List (SCL)-90: Manual I. Baltimore: Johns Hopkins University School of Medicine, 1977.
23. McGarry P, Goodwin R. Brief Psychiatric Rating Scale - Nursing Modification. Canberra: National Health and Medical Research Council, October 1988.
24. Kaplan HL. SMS: A software strategy for acute effects studies. In: Harris LS, ed. Problems of Drug Dependence 1995. Proceedings of the 57th Annual Scientific Meeting, the College on Problems of Drug Dependence, Inc. NIDA Research Monograph # 162. Rockville: United States Department of Health and Human Services, 1996:188.
25. McLean WJ, Frecker RC. Clinical pupilometry system running under MS Windows. Abstracts of the Investigative Ophthalmology and Visual Science Annual Meeting, Sarasota, May 3-8, 1992. (Abst 2278-S8)
26. Haertzen CA, Hill HE, Belleville RE. Development of the Addiction Research Center Inventory (ARCI): Selection of items that are sensitive to the effects of various drugs. Psychopharmacology 1963;4:155-66.
27. Jasinski DR. Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR, ed. Handbook of Experimental Pharmacology, Drug Addiction I. Morphine, Sedative-Hypnotics and Alcohol Dependence. New York: Springer-Verlag, 1977:197-258.
28. Cole JO, Orzack MH, Beake B, Bird M, Bar-Tal Y. Assessment of the abuse liability of buspirone in recreationaly sedative users. J Clin Psychiatry 1982;43:69-75.
29. Johanson, Uhlenhuth EH. Drug preference and mood in humans: D-amphetamine. Psychopharmacology 1980;71:275-9.
30. Johanson CE, Uhlenhuth EH. Drug preference and mood in humans. Diazepam. J Pharmacol Exp Ther 1980;199:67-73.
31. Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Somer G, Sellers EM. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 1997;281:103-8.
32. Chait LD, Uhlenhuth EH, Johanson CE. An experimental paradigm for studying the discriminative stimulus properties of drugs in humans. Psychopharmacology 1984;82:272-4.
33. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B, Woodson PD. Low-dose caffeine discrimination in humans. J Pharmacol Exp Ther 1990;252:970-8.
34. de Wit H. Preference procedures for testing the abuse liability of drugs in humans. Br J Addict 1991;86:1579-85.
35. Kamien JB, Bickel WK, Oliveto AH, et al. Placebo-effects contribute to differences in the acquisition of drug discrimination by humans: A retrospective analysis. Behav Pharmacol 1995;6:187-94.
36. Leber PD, Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Clin Trials 1998;19:178-87.